Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaGlobeNewsWire • 12/06/23
Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great ChoiceZacks Investment Research • 11/30/23
What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'Zacks Investment Research • 11/29/23
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/07/23
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023GlobeNewsWire • 10/31/23
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)GlobeNewsWire • 10/20/23
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsGlobeNewsWire • 09/06/23
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/08/23
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023GlobeNewsWire • 08/02/23
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023GlobeNewsWire • 07/19/23
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsGlobeNewsWire • 07/11/23
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%Zacks Investment Research • 07/04/23
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of JulGlobeNewsWire • 07/03/23
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsGlobeNewsWire • 06/13/23
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/22/23
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/22/23